The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH 2017 | Current research into pro-apoptosis medication for leukemia
The evasion of apoptosis is a hallmark of cancer, which needs to be halted in order to treat malignancies. In this video, Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Alfred Hospital and Monash University, Melbourne, Australia touches upon the mechanism of apoptosis and the use of venetoclax, a drug that can benefit patients with chronic lymphocytic leukaemia. Dr Wei also discusses his research regarding pro-survival proteins in acute myeloid leukemia. This interview was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH).
